Exyte Delivers Record Results in FY 2019
- FY 2019: Sales grew to €3.9 billion (+10.1% vs. 2018); adjusted EBIT up 31.2% YOY
- Exyte expects a moderate impact of the Covid-19 pandemic for FY 2020
Stuttgart, 31 July 2020 – Exyte AG (“Exyte”), a global leader in the design, engineering, and delivery of high-tech facilities, has delivered another record year with sales of €3.9 billion and adjusted EBIT of €223 million in the Fiscal Year (FY) 2019.
In 2019, Exyte generated sales of €3.9 billion (2018: €3.5 billion), growing by 10.1% compared to 2018. Sales growth was particularly pronounced in Europe (EMEA) with an increase by 57.1% year-over-year, due to the award of significant projects in Ireland and Austria. Sales in Asia-Pacific (APAC) and the USA (AMER) were slightly below the 2018 figures. At the same time, EMEA more than doubled its order intake in 2019, thus totaling to a new record high Group order intake of €4.8 billion.
In FY 2019, Exyte boosted profitability and achieved adjusted EBIT of €223 million (€170 million in 2018). The company also improved its adjusted EBIT margin by nearly one percentage point to 5.7%. This increase is mainly attributable to the strategy of a strong focus on core business as well as the completion of highly successful projects.
Dr. Wolfgang Büchele, CEO of Exyte, said, “Given the high benchmark we set ourselves with the exceptional year in 2018, we are very satisfied with the implementation of our strategy and development of our business in 2019. We improved all significant performance indicators. In order to sustain the success and to further grow our business, we set our focus on the continuous optimization of our services, operations, and processes. In 2019, we strengthened our business segments, allowing us to work even more closely together with our clients globally. We will continue to align all our efforts to maximize the full potential of our organization.”
Semiconductor business remains growth driver
Exyte concluded FY 2019 with €3.1 billion in sales in its largest business segment Advanced Technology Facilities (ATF; esp. semiconductors), a year-over-year increase of 13.7% (2018: €2.8 billion). In the ATF segment, Exyte secured significant orders in Asia, Europe, and the USA and grew despite the reduced investments of the semiconductor industry in general.
The other two business segments Life Sciences & Chemicals (LSC) and Data Centers (DTC) developed according to plan. With sales of €304 million and €346 million, respectively, LSC sales were slightly below 2018, while DTC more than doubled its sales volume compared to 2018. The development in both business segments remains a high priority in the longterm strategy of Exyte.
Outlook 2020: positive development despite impacts of Covid-19 pandemic
Like most industries, Exyte has faced challenges caused by the Covid-19 pandemic in the first half of 2020. At the moment, Exyte expects the pandemic to have a marginally negative impact on its business performance.
To view the Financial Statement FY 2019, click here.